Biotechnology News and Research

RSS

AMRI agrees to acquire OsoBio for $110 million

AMRI today announced that it has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, LLC for $110 million in cash.

2 Jun 2014

ProMark test for prostate cancer meets primary endpoint

Today, for the first time, Metamark presents results from the clinical validation study that showed ProMark, the first and only proteomic-based imaging biopsy test, achieved its primary endpoint by accurately differentiating between aggressive and non-aggressive forms of prostate cancer at early stages of disease.

2 Jun 2014

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

2 Jun 2014

Individuals who speak more languages may slow down cognitive decline from aging

New research reveals that bilingualism has a positive effect on cognition later in life. Findings published in Annals of Neurology, a journal of the American Neurological Association and Child Neurology Society, show that individuals who speak two or more languages, even those who acquired the second language in adulthood, may slow down cognitive decline from aging.

2 Jun 2014

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor.

2 Jun 2014

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of favorable clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL).

2 Jun 2014

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

31 May 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago.

31 May 2014

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).

31 May 2014

New software tool helps identify genetic mutations linked to increased risk for cancer

Researchers at The University of Texas MD Anderson Cancer Center and other institutions have applied a newly developed software tool to identify genetic mutations that contribute to a person's increased risk for developing common, complex diseases, such as cancer.

31 May 2014

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC).

31 May 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the presentation of data for its lead drug candidate, ANG1005, a novel paclitaxel-peptide drug conjugate, at the American Society of Clinical Oncology 50th Annual Meeting in Chicago, IL.

31 May 2014

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

Drs. Michael J.P. Lawman and Patricia D. Lawman, founders of the Tampa-based biotech firm Morphogenesis Inc., announce the publication of "Cancer Vaccines: Methods and Protocols," the most definitive work to date in the promising field of cancer vaccines.

31 May 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule, Inc. today announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30, 2014 to June 3, 2014 in Chicago, Illinois.

31 May 2014

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem announced today that the Food & Drug Association (FDA) has granted both orphan drug and fast track designation to ANG1005 a novel paclitaxel-peptide drug conjugate leveraging the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer, for the treatment of glioblastoma multiforme (GBM).

31 May 2014

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701).

31 May 2014

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.

31 May 2014

PGFX Patent Holdings acquires proprietary methods, devices, intellectual property from Orogen Biosciences

On Friday, April 18th PGFX Patent Holdings, operating as Heritage Biosciences, LLC made an asset acquisition of proprietary methods, devices and intellectual property from Orogen Biosciences, Inc.

31 May 2014

GrowBLOX Sciences relocates corporate headquarters to Las Vegas, Nevada

GrowBLOX Sciences, Inc. a biotechnology and research company, announced today that The Company has relocated its corporate headquarters to Las Vegas, Nevada and has centralized its CFO and team in the heart of Clark County in anticipation of its Nevada project.

31 May 2014

Biotechnology News and Research

AMRI agrees to acquire OsoBio for $110 million

ProMark test for prostate cancer meets primary endpoint

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Individuals who speak more languages may slow down cognitive decline from aging

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

ImmunoGen reports favorable clinical results from STARLYTE Phase II trial of SAR3419 for DLBCL

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Amgen presents extended analysis of PEAK study data at ASCO

New software tool helps identify genetic mutations linked to increased risk for cancer

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

ArQule to present tivantinib clinical trial data at ASCO 2014

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

PGFX Patent Holdings acquires proprietary methods, devices, intellectual property from Orogen Biosciences

GrowBLOX Sciences relocates corporate headquarters to Las Vegas, Nevada

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News